Pain biotech Taiwan Liposome decreases proposed US IPO deal size and discloses updated financials

Taiwan Liposome, which is developing lipid formulations of approved drugs for pain and eye disease, lowered the proposed deal size for its upcoming IPO and disclosed updated financials for the nine mo…
( read original story …)

Search your Hotel